Company profile
Vyome Holdings, Inc.
NASDAQ: HIND · Healthcare · Biotechnology
#963 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
33DFH 26DQ 51GM 12SS 44
v0.1 · 65/100 weight · provisional
↑ disclosure history, balance-sheet leverage · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$1.3M
Rev growth YoY (TTM)
-81.3%
Net income (FY)
-$10.3M
Employees
18
as of 2026-08-22
Market cap
$15.8M
as of 2026-08-22
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$319.7k$319.7k2025
Net income-$10.3M-$10.3M2025
Operating income-$10.5M-$10.5M2025
Total assets$6.5M$6.5M2025
Liabilities$2.7M$2.7M2025
Equity$3.8M$3.8M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product55%
License37%
Royalty9%
By geography
Not disclosed.
The read
What is Vyome Holdings, Inc.’s revenue?
Vyome Holdings, Inc. booked $319.7k in FY2025 revenue, contracting 96% year over year — among the slowest-growing Healthcare companies we track, at a -3209.7% net margin.
Peers · Healthcare
Provectus Biopharmaceuticals, Inc.35DGold River Productions, Inc.——Allarity Therapeutics, Inc.25DInteractive Health Network——Medixall Group, Inc.——Atai Beckley Inc.——Neighbors
Mercer →Key facts
CEOVenkateswarlu Nelabhotla
SectorHealthcare
IndustryBiotechnology
HeadquartersPrinceton, NJ
ExchangeNASDAQ: HIND
Employees18
IPO date2016-10-06
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.